Eli Lilly and Company (NYSE:LLY) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 21.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,882 shares of the company’s stock after selling 7,003 shares during the quarter. Great Lakes Advisors LLC’s holdings in Eli Lilly and Company were worth $19,981,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Truvestments Capital LLC grew its holdings in Eli Lilly and Company by 19.1% during the 4th quarter. Truvestments Capital LLC now owns 673 shares of the company’s stock valued at $520,000 after buying an additional 108 shares during the last quarter. Hopwood Financial Services Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $110,000. Farther Finance Advisors LLC grew its holdings in Eli Lilly and Company by 1.1% during the 4th quarter. Farther Finance Advisors LLC now owns 14,125 shares of the company’s stock valued at $10,904,000 after buying an additional 152 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 6.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,043 shares of the company’s stock valued at $3,121,000 after buying an additional 248 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its holdings in Eli Lilly and Company by 48.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 101,735 shares of the company’s stock valued at $78,539,000 after buying an additional 33,245 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.2 %

NYSE:LLY opened at $822.26 on Thursday. The business’s 50-day moving average is $829.78 and its two-hundred day moving average is $845.29. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The firm has a market capitalization of $779.64 billion, a PE ratio of 70.22, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has approved a stock repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a research note on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.